INSILICO (03696.HK): Signs AI co-development deal worth up to tens of millions of USD

NewTimeSpace News: On 21 September 2026, InSilico Medicine (stock code: 3696) published a voluntary announcement that the Company has entered into a collaboration with a frontier foundation model laboratory with a contract value of up to tens of millions of US dollars.

Under the agreement, the parties will jointly develop, validate and commercialise a series of frontier foundation models purpose-built for biological research, leveraging the MMAI Gym training framework. The collaboration terms provide that the parties will deeply integrate their respective strengths to build dedicated foundation models for generative biology. InSilico Medicine will provide proprietary datasets covering a range of specialised life science tasks and conduct closed-loop wet-lab validation of the outputs generated by the foundation models during training. In addition, the parties have established a revenue-sharing model to drive global commercialisation through their respective partner networks in the biopharmaceutical sector.

The announcement also noted that no assurance can be given that any forward-looking statements or matters regarding the Group's business development will be achieved, will actually occur or materialise, or are complete or accurate, and that the financial and other data disclosed are unaudited and unreviewed by its auditors.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.